Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT01931527
The purpose of this study is to learn more about what is the effect of uric acid on oxidative stress and on the way the body metabolizes sugar in obese people. Understanding this may lead to better diseases such as diabetes.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
St Louis, Missouri, 63110, United States
It has been hypothesized that oxidative stress is involved in the pathogenesis of insulin resistance associated with obesity. Circulating uric acid (UA) is the body's major endogenous plasma antioxidant. Therefore, the investigators evaluated whether alterations in serum UA concentration affect: 1) systemic and skeletal muscle oxidative stress, 2) total antioxidant capacity, and 4) skeletal muscle insulin sensitivity during a hyperinsulinemic-euglycemic clamp.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
Other names: Elitek
Time frame: 12 hours after reducing uric acid
Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). A hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotope glucose tracer infusion will be used to measure percent increase in insulin-stimulated glucose uptake in obese subjects with high uric acid before and after uric acid reduction.
Time frame: 12 hours after reducing uric acid
Uric acid will be reduced to 0 with a 30 minute infusion of a uricase (Elitek, Sanofi-Aventis). Systemic (urinary isoprostanes) and skeletal muscle (carbonylated protein ratio) oxidative stress and total antioxidant capacity (plasma TRAP and FRAP) will be measured in obese subjects with high uric acid before and after uric acid reduction. Levels of isoprostanes were normalized to urinary creatinine and reported at ng/mg.
Time frame: Before reducing uric acid
Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle
Time frame: 12 hours after reducing uric acid
Baseline ratio of total carbonylated proteins to the loading control protein Ran in skeletal muscle
Time frame: Before reducing uric acid
Total Radical-Trapping Antioxidant Potential
Time frame: 12 hours after reducing uric acid
Total Radical-Trapping Antioxidant Potential
Time frame: Before reducing uric acid
Ferric-Reducing Antioxidant Potential
Time frame: 12 hours after reducing uric acid
Ferric-Reducing Antioxidant Potential
Washington University School of Medicine
Other
Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation
Acronym: UA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06694012
Arterial Occlusive Diseases, Arteriosclerosis
Sakai, Osaka, Japan
View Trial DetailsNCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial DetailsNCT07204483
Behavior, Behavioral Symptoms
Naha, Okinawa, Japan
View Trial Details